Editas Medicine-JPM-202401.pdf

1、1Corporate PresentationJanuary 2024Dima,Tristan,&Stephanie2Forward Looking StatementsThis presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995.The words anticipate,believe,continue,could,estimate,expect,intend,may

2、,plan,potential,predict,project,target,should,would,and similar expressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words.Forward-looking statements in this presentation include statements regarding the initiation,timi

3、ng,progress and results of the Companys preclinical and clinical studies and its research and development programs,including initiating the adolescent cohort in the RUBY trial in 2024 and establishing in vivo proof-of-concept for an undisclosed indication in 2024,the timing for the Companys receipt

4、and presentation of data from its clinical trials and preclinical studies,including RUBY clinical updates in mid-2024 and by year-end 2024,the potential of,and expectations for,the Companys product candidates,the timing or likelihood of regulatory filings and approvals,the Companys expectations rega

5、rding commercial readiness,and the Companys expectations regarding cash runway.The Company may not actually achieve the plans,intentions,or expectations disclosed in these forward-looking statements,and you should not place undue reliance on these forward-looking statements.Actual results or events

6、could differ materially from the plans,intentions and expectations disclosed in these forward-looking statements as a result of various important factors,including:uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials,including the RUBY and EdiTHAL trial